421 related articles for article (PubMed ID: 33326604)
21. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
Gadisseur A; Berneman Z; Schroyens W; Michiels JJ
Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359
[TBL] [Abstract][Full Text] [Related]
22. Marked von Willebrand factor and factor VIII elevations in severe acute respiratory syndrome coronavirus-2-positive, but not severe acute respiratory syndrome coronavirus-2-negative, pneumonia: a case-control study.
De Cristofaro R; Liuzzo G; Sacco M; Lancellotti S; Pedicino D; Andreotti F
Blood Coagul Fibrinolysis; 2021 Jun; 32(4):285-289. PubMed ID: 33443926
[TBL] [Abstract][Full Text] [Related]
23. Laboratory diagnosis and molecular classification of von Willebrand disease.
Gadisseur A; Hermans C; Berneman Z; Schroyens W; Deckmyn H; Michiels JJ
Acta Haematol; 2009; 121(2-3):71-84. PubMed ID: 19506352
[TBL] [Abstract][Full Text] [Related]
24. Enhanced VWF clearance in low VWF pathogenesis: limitations of the VWFpp/VWF:Ag ratio and clinical significance.
Doherty D; Michelle Lavin ; Byrne M; Nolan M; O'Sullivan JM; Ryan K; O'Connell NM; Haberichter SL; Christopherson PA; Di Paola J; James PD; O'Donnell JS
Blood Adv; 2023 Feb; 7(3):302-308. PubMed ID: 35523118
[TBL] [Abstract][Full Text] [Related]
25. ADAMTS13 regulation of VWF multimer distribution in severe COVID-19.
Ward SE; Fogarty H; Karampini E; Lavin M; Schneppenheim S; Dittmer R; Morrin H; Glavey S; Ni Cheallaigh C; Bergin C; Martin-Loeches I; Mallon PW; Curley GF; Baker RI; Budde U; O'Sullivan JM; O'Donnell JS;
J Thromb Haemost; 2021 Aug; 19(8):1914-1921. PubMed ID: 34053187
[TBL] [Abstract][Full Text] [Related]
26. Assessment of von Willebrand factor propeptide improves the diagnosis of von Willebrand disease.
Casonato A; Daidone V; Padrini R
Semin Thromb Hemost; 2011 Jul; 37(5):456-63. PubMed ID: 22102187
[TBL] [Abstract][Full Text] [Related]
27. Behavior of ADAMTS13 and Von Willebrand factor levels in patients after living donor liver transplantation.
Takahashi N; Wada H; Usui M; Kobayashi T; Habe-Ito N; Matsumoto T; Uemoto S; Nobori T; Isaji S
Thromb Res; 2013 Mar; 131(3):225-9. PubMed ID: 23266519
[TBL] [Abstract][Full Text] [Related]
28. von Willebrand factor: evidence for variable clearance in vivo according to Y/C1584 phenotype and ABO blood group.
Davies JA; Collins PW; Hathaway LS; Bowen DJ
J Thromb Haemost; 2008 Jan; 6(1):97-103. PubMed ID: 17949477
[TBL] [Abstract][Full Text] [Related]
29. Assay of the von Willebrand factor (VWF) propeptide to identify patients with type 1 von Willebrand disease with decreased VWF survival.
Haberichter SL; Balistreri M; Christopherson P; Morateck P; Gavazova S; Bellissimo DB; Manco-Johnson MJ; Gill JC; Montgomery RR
Blood; 2006 Nov; 108(10):3344-51. PubMed ID: 16835381
[TBL] [Abstract][Full Text] [Related]
30. von Willebrand Factor Propeptide: A Potential Disease Biomarker Not Affected by ABO Blood Groups.
Marianor M; Zaidah AW; Maraina ChC
Biomark Insights; 2015; 10():75-9. PubMed ID: 26339184
[TBL] [Abstract][Full Text] [Related]
31. von Willebrand factor propeptide in vascular disorders: A tool to distinguish between acute and chronic endothelial cell perturbation.
van Mourik JA; Boertjes R; Huisveld IA; Fijnvandraat K; Pajkrt D; van Genderen PJ; Fijnheer R
Blood; 1999 Jul; 94(1):179-85. PubMed ID: 10381511
[TBL] [Abstract][Full Text] [Related]
32. von Willebrand factor propeptide: biology and clinical utility.
Haberichter SL
Blood; 2015 Oct; 126(15):1753-61. PubMed ID: 26215113
[TBL] [Abstract][Full Text] [Related]
33. Plasma ADAMTS13, von Willebrand factor (VWF) and VWF propeptide profiles in patients with DIC and related diseases.
Habe K; Wada H; Ito-Habe N; Hatada T; Matsumoto T; Ohishi K; Maruyama K; Imai H; Mizutani H; Nobori T
Thromb Res; 2012 May; 129(5):598-602. PubMed ID: 22070827
[TBL] [Abstract][Full Text] [Related]
34. Gene silencing of endothelial von Willebrand factor reduces the susceptibility of human endothelial cells to SARS-CoV-2 infection.
Furini G; De Carli A; Fonnesu R; Spezia PG; Scebba F; Pistello M; Lai M; Lionetti V
FEBS J; 2023 Sep; 290(17):4300-4315. PubMed ID: 37098810
[TBL] [Abstract][Full Text] [Related]
35. Quantitative analysis of von Willebrand factor and its propeptide in plasma in acquired von Willebrand syndrome.
van Genderen PJ; Boertjes RC; van Mourik JA
Thromb Haemost; 1998 Sep; 80(3):495-8. PubMed ID: 9759633
[TBL] [Abstract][Full Text] [Related]
36. Elevated Von Willebrand factor propeptide for the diagnosis of thrombotic microangiopathy and for predicting a poor outcome.
Ito-Habe N; Wada H; Matsumoto T; Ohishi K; Toyoda H; Ishikawa E; Nomura S; Komada Y; Ito M; Nobori T; Katayama N
Int J Hematol; 2011 Jan; 93(1):47-52. PubMed ID: 21153061
[TBL] [Abstract][Full Text] [Related]
37. Role of von Willebrand Factor in COVID-19 Associated Coagulopathy.
Mei ZW; van Wijk XMR; Pham HP; Marin MJ
J Appl Lab Med; 2021 Sep; 6(5):1305-1315. PubMed ID: 33930144
[TBL] [Abstract][Full Text] [Related]
38. Correlation between von Willebrand factor antigen, von Willebrand factor ristocetin cofactor activity and factor VIII activity in plasma.
Lippi G; Franchini M; Salvagno GL; Montagnana M; Poli G; Guidi GC
J Thromb Thrombolysis; 2008 Oct; 26(2):150-3. PubMed ID: 17786534
[TBL] [Abstract][Full Text] [Related]
39. von Willebrand factor propeptide in malaria: evidence of acute endothelial cell activation.
Hollestelle MJ; Donkor C; Mantey EA; Chakravorty SJ; Craig A; Akoto AO; O'Donnell J; van Mourik JA; Bunn J
Br J Haematol; 2006 Jun; 133(5):562-9. PubMed ID: 16681646
[TBL] [Abstract][Full Text] [Related]
40. Critical independent regions in the VWF propeptide and mature VWF that enable normal VWF storage.
Haberichter SL; Jacobi P; Montgomery RR
Blood; 2003 Feb; 101(4):1384-91. PubMed ID: 12393513
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
